Pikor Larissa A, Enfield Katey S S, Cameron Heryet, Lam Wan L
Department of Integrative Oncology, BC Cancer Research Centre, Canada.
J Vis Exp. 2011 Mar 26(49):2763. doi: 10.3791/2763.
Disease development and progression are characterized by frequent genetic and epigenetic aberrations including chromosomal rearrangements, copy number gains and losses and DNA methylation. Advances in high-throughput, genome-wide profiling technologies, such as microarrays, have significantly improved our ability to identify and detect these specific alterations. However as technology continues to improve, a limiting factor remains sample quality and availability. Furthermore, follow-up clinical information and disease outcome are often collected years after the initial specimen collection. Specimens, typically formalin-fixed and paraffin embedded (FFPE), are stored in hospital archives for years to decades. DNA can be efficiently and effectively recovered from paraffin-embedded specimens if the appropriate method of extraction is applied. High quality DNA extracted from properly preserved and stored specimens can support quantitative assays for comparisons of normal and diseased tissues and generation of genetic and epigenetic signatures (1). To extract DNA from paraffin-embedded samples, tissue cores or microdissected tissue are subjected to xylene treatment, which dissolves the paraffin from the tissue, and then rehydrated using a series of ethanol washes. Proteins and harmful enzymes such as nucleases are subsequently digested by proteinase K. The addition of lysis buffer, which contains denaturing agents such as sodium dodecyl sulfate (SDS), facilitates digestion (2). Nucleic acids are purified from the tissue lysate using buffer-saturated phenol and high speed centrifugation which generates a biphasic solution. DNA and RNA remain in the upper aqueous phase, while proteins, lipids and polysaccharides are sequestered in the inter- and organic-phases respectively. Retention of the aqueous phase and repeated phenol extractions generates a clean sample. Following phenol extractions, RNase A is added to eliminate contaminating RNA. Additional phenol extractions following incubation with RNase A are used to remove any remaining enzyme. The addition of sodium acetate and isopropanol precipitates DNA, and high speed centrifugation is used to pellet the DNA and facilitate isopropanol removal. Excess salts carried over from precipitation can interfere with subsequent enzymatic assays, but can be removed from the DNA by washing with 70% ethanol, followed by centrifugation to re-pellet the DNA (3). DNA is re-suspended in distilled water or the buffer of choice, quantified and stored at -20°C. Purified DNA can subsequently be used in downstream applications which include, but are not limited to, PCR, array comparative genomic hybridization (4) (array CGH), methylated DNA Immunoprecipitation (MeDIP) and sequencing, allowing for an integrative analysis of tissue/tumor samples.
疾病的发生和发展具有频繁的遗传和表观遗传异常特征,包括染色体重排、拷贝数增加和减少以及DNA甲基化。高通量、全基因组分析技术(如微阵列)的进展显著提高了我们识别和检测这些特定改变的能力。然而,随着技术不断改进,一个限制因素仍然是样本质量和可获得性。此外,后续临床信息和疾病转归通常在最初标本采集数年之后才收集。标本通常为福尔马林固定石蜡包埋(FFPE),在医院档案中保存数年至数十年。如果应用适当的提取方法,DNA可以从石蜡包埋标本中高效且有效地回收。从妥善保存和储存的标本中提取的高质量DNA可支持对正常和患病组织进行比较的定量分析以及生成遗传和表观遗传特征(1)。为了从石蜡包埋样本中提取DNA,将组织芯或显微切割组织进行二甲苯处理,二甲苯可溶解组织中的石蜡,然后通过一系列乙醇洗涤进行复水。随后用蛋白酶K消化蛋白质和有害酶(如核酸酶)。加入含有变性剂(如十二烷基硫酸钠(SDS))的裂解缓冲液有助于消化(2)。使用缓冲液饱和苯酚和高速离心从组织裂解物中纯化核酸,高速离心产生双相溶液。DNA和RNA保留在上层水相中,而蛋白质、脂质和多糖分别被隔离在中间相和有机相中。保留水相并重复苯酚提取可得到纯净样本。苯酚提取后,加入RNase A以消除污染的RNA。与RNase A孵育后再进行额外的苯酚提取以去除任何残留的酶。加入醋酸钠和异丙醇沉淀DNA,并用高速离心使DNA沉淀并便于去除异丙醇。沉淀过程中残留的过量盐会干扰后续酶促分析,但可通过用70%乙醇洗涤DNA,然后离心使DNA重新沉淀来去除(3)。将DNA重悬于蒸馏水或所选缓冲液中,进行定量并储存在-20°C。纯化的DNA随后可用于下游应用,包括但不限于PCR、阵列比较基因组杂交(4)(阵列CGH)、甲基化DNA免疫沉淀(MeDIP)和测序,从而对组织/肿瘤样本进行综合分析。